Gonadal steroids in athletic women contraception, complications and performance

Sports Med, 2(4), 287-295

DOI 10.2165/00007256-198502040-00006 PMID 3849058

Abstract

Gonadal steroids are altered by the reproductive system's adaptation to conditioning exercise. Contraceptive options for the athletic woman include all measures appropriate for the sedentary woman. Barrier methods (always with spermicidal jelly) are the preferred choice. The cardiovascular risks, decreased aerobic performance, and shorter time to muscular exhaustion related to oral contraceptives make this a less desirable option. Potential complications from the steroid changes of intense exercise include: low oestrogen and progesterone with risk of loss of trabecular bone and early osteoporosis, and absent progesterone with low normal oestrogen levels associated with risk of endometrial or breast cancer. Therapeutic options for the amenorrhoeic or young athlete include supplemental oral calcium, cyclic oral progesterone, or possibly cyclic physiological oestrogen and progesterone. The anovulatory (usually older) athlete with regular menses needs cyclic progesterone. Medroxyprogesterone 10mg on days 16 to 25 of the cycle or for 10 days monthly can potentially prevent endometrial and breast cancer, give predictable cycles, improve trabecular bone balance and stimulate the return of ovulatory cycles. A practical approach to anovulatory infertility in the athlete includes a 10% reduction in exercise intensity and/or an increase in percentage body fat to 18 to 20%. Cyclic vaginal progesterone (25mg bid) can then treat short luteal phase cycles. With improved understanding of the hormonal adaptations to conditioning exercise, we will be better able to outline contraceptive and therapeutic options in the future.

Topics

Prior Vigna athletic women gonadal steroids exercise, female athlete menstrual dysfunction anovulation treatment, exercise induced amenorrhea cyclic progesterone therapy, athletic women bone loss osteoporosis low estrogen progesterone, anovulatory athlete medroxyprogesterone cyclic treatment, Prior JC progesterone bone density athletic women, contraception athletic women oral contraceptive aerobic performance, exercise amenorrhea breast cancer endometrial cancer risk, short luteal phase athlete vaginal progesterone treatment, anovulatory infertility exercise reduction body fat percentage, female athlete triad hormonal adaptation conditioning exercise
PMID 3849058 3849058 DOI 10.2165/00007256-198502040-00006 10.2165/00007256-198502040-00006

Cite this article

J C Prior, & Y Vigna (1985). Gonadal steroids in athletic women contraception, complications and performance. *Sports medicine (Auckland, N.Z.)*, *2*(4), 287-295. https://doi.org/10.2165/00007256-198502040-00006

Related articles